Skip to main content
. Author manuscript; available in PMC: 2020 Jul 5.
Published in final edited form as: Pharm Res. 2016 Jun 9;33(9):2298–2306. doi: 10.1007/s11095-016-1968-3

Fig. 3.

Fig. 3

Assessment of therapeutic activities of a single injection of IP empty hydrogels, IP TheranoGel, IP TheranoMic, and IV TheranoMic in whole-body bioluminescence images (a) and relative bioluminescence intensity of ROIs in a time-dependent manner (b). Assessment of diagnostic activities of a single injection of IP TheranoGel, IP TheranoMic, and IV TheranoMic in fluorescence images post-treatment, before, during, and after the surgery (c) (*p < 0.05; TheranoMic (IV) versus TheranoGel (IP) at day 3, ***p < 0.001; control versus TheranoGel (IP) at day 3).